BRPI0607346A2 - compostos inibidores de raf e métodos - Google Patents
compostos inibidores de raf e métodosInfo
- Publication number
- BRPI0607346A2 BRPI0607346A2 BRPI0607346-8A BRPI0607346A BRPI0607346A2 BR PI0607346 A2 BRPI0607346 A2 BR PI0607346A2 BR PI0607346 A BRPI0607346 A BR PI0607346A BR PI0607346 A2 BRPI0607346 A2 BR PI0607346A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- inhibitor compounds
- raf inhibitor
- raf
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
COMPOSTOS INIBIDORES DE RAF E MéTODOS. Compostos de pirazolila de Fórmulas Ia e Ib são úteis para inibição de Raf cinase e para tratamento de distúrbios mediados por esta. Métodos de uso de compostos de pirazolila para diagnóstico, prevenção ou tratamento in vitro, in situ e in vivo de tais distúrbios em células de mamíferos, ou condições patológicas associadas, são descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65005005P | 2005-02-04 | 2005-02-04 | |
PCT/US2006/003654 WO2006084015A2 (en) | 2005-02-04 | 2006-02-02 | Raf inhibitor compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607346A2 true BRPI0607346A2 (pt) | 2009-09-01 |
Family
ID=36571626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607346-8A BRPI0607346A2 (pt) | 2005-02-04 | 2006-02-02 | compostos inibidores de raf e métodos |
Country Status (18)
Country | Link |
---|---|
US (2) | US7491829B2 (pt) |
EP (1) | EP1846391A2 (pt) |
JP (1) | JP2008530011A (pt) |
KR (1) | KR20070107104A (pt) |
CN (1) | CN101282960A (pt) |
AR (1) | AR053014A1 (pt) |
AU (1) | AU2006210626A1 (pt) |
BR (1) | BRPI0607346A2 (pt) |
CA (1) | CA2596973A1 (pt) |
CR (1) | CR9365A (pt) |
IL (1) | IL185024A0 (pt) |
MA (1) | MA29310B1 (pt) |
MX (1) | MX2007009405A (pt) |
NO (1) | NO20074473L (pt) |
RU (1) | RU2007133111A (pt) |
TW (1) | TW200639163A (pt) |
WO (1) | WO2006084015A2 (pt) |
ZA (1) | ZA200707289B (pt) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
CN101611016B (zh) | 2006-10-17 | 2012-01-25 | 斯蒂菲尔实验室公司 | 他拉罗唑代谢物 |
JP2010540451A (ja) * | 2007-09-20 | 2010-12-24 | ワイス・エルエルシー | ピラゾロ[5,1−c][1,2,4]トリアジン、その調製法および使用法 |
JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
CL2009000447A1 (es) * | 2008-02-29 | 2010-01-04 | Array Biopharma Inc Y Genentech Inc | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. |
AR072657A1 (es) * | 2008-02-29 | 2010-09-15 | Genentech Inc | Compuestos inhibidores de raf y metodos para su uso |
WO2009111260A1 (en) * | 2008-02-29 | 2009-09-11 | Wyeth | Phenylsulfonamide-substituted, pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | RAF阻害化合物として使用されるイミダゾ[4,5−b]ピリジン誘導体 |
WO2009108827A1 (en) * | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
JP2009286773A (ja) * | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
WO2010068292A1 (en) * | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
EP2470539A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025938A2 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
EP2470532A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase |
CA2771893A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
US20120214811A1 (en) | 2009-08-28 | 2012-08-23 | Ignacio Aliagas | Raf inhibitor compounds and methods of use thereof |
EP2470538A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
ES2522827T3 (es) * | 2009-10-30 | 2014-11-18 | Domain Therapeutics | Nuevos derivados de oximas y su uso como moduladores alostéricos de los receptores del glutamato metabotrópico |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2519526B1 (en) | 2009-12-31 | 2014-03-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Tricyclic compounds for use as kinase inhibitors |
US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
EP2423210A1 (de) | 2010-08-25 | 2012-02-29 | Bayer CropScience AG | Heteroarylpiperidin- und -piperazinderivate als Fungizide |
US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
WO2012055837A1 (de) | 2010-10-27 | 2012-05-03 | Bayer Cropscience Ag | Heteroarylpiperidin und -piperazinderivate als fungizide |
WO2012094451A1 (en) | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
BR112013019667B1 (pt) | 2011-02-01 | 2019-07-02 | Bayer Intellectual Property Gmbh | Compostos derivados de heteroaril-piperidina e -piperazina, seus usos, composição, processos de produção de compostos e de composições, método para o controle de fungos fitopatogênicos prejudiciais |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
BR112014006419A2 (pt) | 2011-09-19 | 2018-08-07 | Genentech Inc | métodos para tratar um paciente com câncer, kit e artigo |
JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN107266382B (zh) | 2011-12-27 | 2020-10-27 | 拜耳知识产权有限责任公司 | 作为杀菌剂的杂芳基哌啶和杂芳基哌嗪衍生物 |
AU2011384857B2 (en) | 2011-12-31 | 2016-03-03 | Beigene, Ltd. | Fused tricyclic compounds as Raf kinase inhibitors |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
SG10201708494QA (en) | 2012-08-17 | 2017-11-29 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
JP2016520528A (ja) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | 癌の治療及び抗癌剤耐性の防止方法 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
CN107011441B (zh) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
WO2015196072A2 (en) * | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
EP3169361B1 (en) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
JP6909153B2 (ja) | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗pd−l1抗体 |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
US10351559B2 (en) | 2015-04-15 | 2019-07-16 | Beigene, Ltd. | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
CA3004348A1 (en) | 2015-11-19 | 2017-05-26 | Genentech, Inc. | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
IL294423B2 (en) * | 2016-12-23 | 2024-01-01 | Univ Yale | Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF |
WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
CA3086765A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
WO2022089604A1 (en) * | 2020-10-30 | 2022-05-05 | Novartis Ag | New crystalline forms of a kras g12c inhibitor compound |
CA3234264A1 (en) * | 2021-11-30 | 2023-06-08 | Haibing DENG | Pyrazole derivative, and preparation method therefor and use thereof in medicine |
WO2024022186A1 (zh) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
JPH05125079A (ja) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | ピラゾロ[1,5−aピリミジン誘導体 |
KR100315837B1 (ko) | 1994-06-21 | 2002-02-28 | 고리 히데아끼 | 피라졸로[1,5-a]피리미딘유도체 |
US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
EP0795555A4 (en) | 1995-09-28 | 1998-01-07 | Otsuka Pharma Co Ltd | ANALGETICS |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
EP0983260A2 (en) | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
JP2000153671A (ja) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
WO2000064422A2 (en) | 1999-04-27 | 2000-11-02 | Smithkline Beecham P.L.C. | Novel treatment of neurotraumatic conditions with raf inhibitor |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
EP1200422A2 (en) | 2000-02-05 | 2002-05-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
CA2369502A1 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
JP4739632B2 (ja) | 2000-02-05 | 2011-08-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erkのインヒビターとして有用なピラゾール組成物 |
WO2001066539A1 (en) | 2000-03-06 | 2001-09-13 | Smithkline Beecham P.L.C. | Imidazol derivatives as raf kinase inhibitors |
EP1318992B1 (en) | 2000-09-21 | 2005-07-27 | Smithkline Beecham Plc | Imidazole derivatives as raf kinase inhibitors |
CN1274690C (zh) | 2000-12-28 | 2006-09-13 | 小野药品工业株式会社 | 三杂环化合物和包括其作为活性组分的药物 |
ATE377598T1 (de) | 2001-01-22 | 2007-11-15 | Sankyo Co | Durch bicyclische aminogruppen substituierte verbindungen |
CA2440211A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
WO2002088107A1 (en) * | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
SI1397364T1 (sl) | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
EP1423382B1 (en) | 2001-08-03 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
DE60238620D1 (de) | 2001-08-03 | 2011-01-27 | Vertex Pharma | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
ES2295441T3 (es) * | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
ATE374753T1 (de) * | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
DE60314623T2 (de) | 2002-05-10 | 2008-02-28 | Smithkline Beecham Corp. | Substituierte pyrazolopyrimidine |
GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
AR040726A1 (es) | 2002-07-31 | 2005-04-20 | Smithkline Beecham Corp | Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento |
ATE343572T1 (de) * | 2002-08-09 | 2006-11-15 | Lilly Co Eli | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
PL379544A1 (pl) | 2002-09-09 | 2006-10-02 | Amgen Inc. | 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych |
US7365066B2 (en) | 2002-09-17 | 2008-04-29 | Eli Lilly And Company | Pyrazolopyridine derivatives as pharmaceutical agents |
MXPA05002376A (es) | 2002-09-18 | 2005-05-23 | Pfizer Prod Inc | Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf). |
AU2003268155A1 (en) | 2002-09-19 | 2004-04-08 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2006
- 2006-01-27 TW TW095103640A patent/TW200639163A/zh unknown
- 2006-02-02 RU RU2007133111/04A patent/RU2007133111A/ru not_active Application Discontinuation
- 2006-02-02 EP EP06734199A patent/EP1846391A2/en not_active Withdrawn
- 2006-02-02 CN CNA2006800109351A patent/CN101282960A/zh active Pending
- 2006-02-02 JP JP2007554205A patent/JP2008530011A/ja active Pending
- 2006-02-02 BR BRPI0607346-8A patent/BRPI0607346A2/pt not_active IP Right Cessation
- 2006-02-02 US US11/345,828 patent/US7491829B2/en not_active Expired - Fee Related
- 2006-02-02 KR KR1020077020119A patent/KR20070107104A/ko not_active Application Discontinuation
- 2006-02-02 MX MX2007009405A patent/MX2007009405A/es not_active Application Discontinuation
- 2006-02-02 CA CA002596973A patent/CA2596973A1/en not_active Abandoned
- 2006-02-02 WO PCT/US2006/003654 patent/WO2006084015A2/en active Application Filing
- 2006-02-02 AU AU2006210626A patent/AU2006210626A1/en not_active Abandoned
- 2006-02-03 AR ARP060100401A patent/AR053014A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185024A patent/IL185024A0/en unknown
- 2007-08-17 MA MA30151A patent/MA29310B1/fr unknown
- 2007-08-28 ZA ZA200707289A patent/ZA200707289B/xx unknown
- 2007-09-03 NO NO20074473A patent/NO20074473L/no not_active Application Discontinuation
- 2007-09-04 CR CR9365A patent/CR9365A/es not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,412 patent/US20090176809A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR053014A1 (es) | 2007-04-18 |
US7491829B2 (en) | 2009-02-17 |
US20090176809A1 (en) | 2009-07-09 |
CN101282960A (zh) | 2008-10-08 |
ZA200707289B (en) | 2009-09-30 |
TW200639163A (en) | 2006-11-16 |
RU2007133111A (ru) | 2009-03-10 |
MX2007009405A (es) | 2007-09-25 |
CA2596973A1 (en) | 2006-08-10 |
JP2008530011A (ja) | 2008-08-07 |
US20060189627A1 (en) | 2006-08-24 |
NO20074473L (no) | 2007-10-31 |
WO2006084015A3 (en) | 2006-11-23 |
AU2006210626A1 (en) | 2006-08-10 |
IL185024A0 (en) | 2007-12-03 |
MA29310B1 (fr) | 2008-03-03 |
CR9365A (es) | 2008-01-15 |
WO2006084015A2 (en) | 2006-08-10 |
EP1846391A2 (en) | 2007-10-24 |
KR20070107104A (ko) | 2007-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607346A2 (pt) | compostos inibidores de raf e métodos | |
BR112012008624A2 (pt) | inibidores de tirosina quinase de bruton | |
WO2006125101A3 (en) | Raf inhibitor compounds and methods of use thereof | |
ECSP10010507A (es) | Pirazolo (3, 4-b) piridina inhibidores de raf | |
NO20084183L (no) | Heterobisykliske pyrazolforbindelser og fremgangsmater for anvendelse | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
NO20073921L (no) | Triazoloftalaziner | |
WO2009111278A3 (en) | Raf inhibitor compounds and methods of use thereof | |
UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
NO20084927L (no) | Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
WO2010005876A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
BRPI0514537B8 (pt) | compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende | |
WO2007051065A3 (en) | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase | |
ECSP088598A (es) | Derivados de piridazinona | |
CL2009000316A1 (es) | Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos. | |
ECSP13012692A (es) | Compuestos tricíclicos inhibidores de la pi3k y métodos de uso | |
MX2009011211A (es) | Indoles sustituidos en la posicion 7 inhibidores de mci-1. | |
SG178986A1 (en) | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | |
WO2008063202A3 (en) | Heterobicyclic thiophene compounds for the treatment of cancer | |
EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
BRPI0513915A (pt) | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
MX354402B (es) | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 8A. ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2272 DE 22/07/2014. |